Page last updated: 2024-11-07

prednisone and HIV

prednisone has been researched along with HIV in 19 studies

Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.

HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.

Research Excerpts

ExcerptRelevanceReference
"To examine the effect of 2 weeks of treatment with prednisone on the incidence of nevirapine-associated rash in HIV-1-infected patients receiving combination antiretroviral therapy."9.10Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. ( Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003)
"This is a phase 2 study to assess the role of tumor histogenesis (subtype), fluorodeoxyglucose positron emission tomography (FDG-PET), and short-course etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin with dose-dense rituximab (SC-EPOCH-RR) in newly diagnosed HIV-associated CD20(+) diffuse large B-cell lymphoma."5.14The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. ( Carrasquillo, JA; Dunleavy, K; Grant, N; Jaffe, ES; Little, RF; Pittaluga, S; Steinberg, SM; Wayne, AS; Wilson, WH; Yarchoan, R, 2010)
"To examine the effect of 2 weeks of treatment with prednisone on the incidence of nevirapine-associated rash in HIV-1-infected patients receiving combination antiretroviral therapy."5.10Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. ( Cahn, P; Casssetti, LI; Gigliotti, M; Hall, DB; Losso, M; McDonough, M; Montaner, JS; Robinson, PA; Wruck, J; Zala, C, 2003)
" Our study aimed to investigate the prognosis and compare outcome of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab(R-CHOP) as front line therapy for PLHIV with diffuse large B-cell lymphoma (DLBCL) receiving modern combined antiretroviral therapy (cART)."3.96Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China. ( Chen, J; Liu, L; Qi, TK; Shen, YZ; Song, W; Sun, JJ; Tang, Y; Wang, JR; Wang, ZY; Zhang, RF, 2020)
"Limited comparative data exist for the treatment of HIV-associated non-Hodgkin lymphoma."2.49Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. ( Barta, SK; Boue, F; Dunleavy, K; Galicier, L; Garcia, O; Kaplan, LD; Lee, JY; Little, RF; Morgades, M; Mounier, N; Navarro, JT; Noy, A; Oriol, A; Ratner, L; Remick, SC; Ribera, JM; Sparano, JA; Spina, M; Tamari, R; Tirelli, U; Wang, D; Weiss, R; Wilson, WH; Wyen, C; Xue, X, 2013)

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19902 (10.53)18.7374
1990's2 (10.53)18.2507
2000's6 (31.58)29.6817
2010's5 (26.32)24.3611
2020's4 (21.05)2.80

Authors

AuthorsStudies
Rapiti, N1
Abdelatif, N1
Rapiti, A1
Moosa, MY1
Sun, JJ1
Liu, L1
Wang, JR1
Shen, YZ1
Qi, TK1
Wang, ZY1
Tang, Y1
Song, W1
Chen, J1
Zhang, RF1
Ke, YL1
Hsiao, HH1
Cho, SF1
Wu, CC1
Harrison, MJ1
Brice, N1
Scott, C1
Barta, SK1
Xue, X1
Wang, D1
Tamari, R1
Lee, JY2
Mounier, N1
Kaplan, LD2
Ribera, JM1
Spina, M2
Tirelli, U2
Weiss, R1
Galicier, L1
Boue, F1
Wilson, WH2
Wyen, C1
Oriol, A1
Navarro, JT1
Dunleavy, K2
Little, RF2
Ratner, L2
Garcia, O1
Morgades, M1
Remick, SC2
Noy, A2
Sparano, JA2
Koizumi, Y1
Uehira, T1
Ota, Y1
Ogawa, Y1
Yajima, K1
Tanuma, J1
Yotsumoto, M1
Hagiwara, S1
Ikegaya, S1
Watanabe, D1
Minamiguchi, H1
Hodohara, K1
Murotani, K1
Mikamo, H1
Wada, H1
Ajisawa, A1
Shirasaka, T1
Nagai, H1
Kodama, Y1
Hishima, T1
Mochizuki, M1
Katano, H1
Okada, S1
Andhavarapu, S1
Tolentino, AM1
Jha, C1
Ravi, J1
Carlson, R1
Nair, GR1
Levine, AM1
Ramos, JC1
Ambinder, RF1
Wachsman, W1
Aboulafia, D1
Henry, DH1
Von Roenn, J1
Dezube, BJ1
Shah, MH1
Leichman, L1
Cesarman, E1
Chadburn, A1
Mitsuyasu, R1
Pittaluga, S1
Grant, N1
Wayne, AS1
Carrasquillo, JA1
Steinberg, SM1
Yarchoan, R1
Jaffe, ES1
Mihaljevic, BS1
Todorovic, MR1
Andjelic, BM1
Antic, DA1
Perunicic Jovanovic, MD1
Montaner, JS1
Cahn, P1
Zala, C1
Casssetti, LI1
Losso, M1
Hall, DB1
Wruck, J1
McDonough, M1
Gigliotti, M1
Robinson, PA1
Tavel, JA1
Sereti, I1
Walker, RE1
Hahn, B1
Kovacs, JA1
Jagannatha, S1
Davey, RT1
Falloon, J1
Polis, MA1
Masur, H1
Metcalf, JA1
Stevens, R1
Rupert, A1
Baseler, M1
Lane, HC1
Youngster, I1
Vaisben, E1
Cohen, H1
Nassar, F1
Rossi, G1
Donisi, A1
Casari, S1
Re, A1
Stellini, R1
Cadeo, G1
Carosi, G1
Gabarre, J1
Fasan, M1
Vaccher, E1
Cornfield, DB1
Papiez, JS1
Lynch, JT1
Rimsza, LM1
Miller, RG1
Laurence, J1
Sellers, MB1
Sikder, SK1
Kerman, RH1
Flechner, SM1
Van Buren, CT1
Lorber, MI1
Dawson, G1
Falk, L1
Gutierrez, R1
Hollinger, JB1
Kahan, BD1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Phase II Trial of EPOCH Given Either Concurrently or Sequentially With Rituximab in Patients With Intermediate- or High-Grade HIV-Associated B-cell Non-Hodgkin's Lymphoma[NCT00049036]Phase 2106 participants (Actual)Interventional2003-03-31Completed
EPOCH Chemotherapy Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma[NCT00001563]Phase 239 participants (Actual)Interventional1997-01-08Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment

Complete response defined by the International Response Criteria for Non-Hodgkin's Lymphoma (NCT00049036)
Timeframe: 60 days

Interventionproportion (Number)
EPOCH + Concurrent Rituximab0.69
EPOCH Followed by Rituximab0.53

Reviews

4 reviews available for prednisone and HIV

ArticleYear
Patient characteristics and outcome of CD20-positive HIV-associated lymphoma: a single-center KwaZulu-Natal, South African hospital 12-year retrospective review.
    Journal of the Egyptian National Cancer Institute, 2022, Aug-01, Volume: 34, Issue:1

    Topics: Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclo

2022
Clinical Features of HIV Arthropathy in Children: A Case Series and Literature Review.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Anti-HIV Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis; CD4 Lymph

2021
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients.
    Blood, 2013, Nov-07, Volume: 122, Issue:19

    Topics: Anti-HIV Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combi

2013
Neuropathies and myopathies complicating HIV infection.
    Journal of clinical apheresis, 1991, Volume: 6, Issue:2

    Topics: Acquired Immunodeficiency Syndrome; Action Potentials; Adult; Antiviral Agents; Azathioprine; Combin

1991

Trials

6 trials available for prednisone and HIV

ArticleYear
Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma.
    Blood, 2010, Apr-15, Volume: 115, Issue:15

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine

2010
The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma.
    Blood, 2010, Apr-15, Volume: 115, Issue:15

    Topics: Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Ag

2010
Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.
    Journal of acquired immune deficiency syndromes (1999), 2003, May-01, Volume: 33, Issue:1

    Topics: CD4 Lymphocyte Count; Drug Administration Schedule; Exanthema; Female; HIV; HIV Infections; Humans;

2003
A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.
    The Journal of infectious diseases, 2003, Aug-15, Volume: 188, Issue:4

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphoc

2003
Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL).
    Haematologica, 1998, Volume: 83, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cohort Studies; Cyclophosphamide;

1998
Stanford V regimen and concomitant highly active antiretroviral therapy is feasible and active in patients with Hodgkin's disease and HIV infection.
    AIDS (London, England), 2000, Jul-07, Volume: 14, Issue:10

    Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Doxorubicin; Etop

2000

Other Studies

9 other studies available for prednisone and HIV

ArticleYear
Clinical outcomes of people living with human immunodeficiency virus (HIV) with diffuse large B-cell lymphoma (DLBCL) in Shanghai, China.
    Chinese medical journal, 2020, Dec-05, Volume: 133, Issue:23

    Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cyclophosphamide; Doxorubicin; HIV; HIV Infec

2020
A tip of the iceberg: Disseminated plasmablastic lymphoma, diagnosed from a local oral lesion.
    The Kaohsiung journal of medical sciences, 2021, Volume: 37, Issue:4

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Biopsy

2021
Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases.
    International journal of hematology, 2016, Volume: 104, Issue:6

    Topics: Adult; Anti-Retroviral Agents; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count;

2016
Diffuse large B-cell lymphoma presenting as multiple lymphomatous polyposis of the gastrointestinal tract.
    Clinical lymphoma & myeloma, 2008, Volume: 8, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Differential; Doxorubic

2008
Unusual presentation of gastric plasmablastic lymphoma in HIV-negative patient.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; HIV; HIV Infections;

2012
An unusual cause of pleural effusion.
    Age and ageing, 2006, Volume: 35, Issue:1

    Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diagnosis, Diff

2006
Natural killer-like T-cell lymphoma of the parotid in a patient infected with human immunodeficiency virus.
    Archives of pathology & laboratory medicine, 2002, Volume: 126, Issue:6

    Topics: Adult; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophospha

2002
Effect of glucocorticoids on chronic human immunodeficiency virus (HIV) infection and HIV promoter-mediated transcription.
    Blood, 1989, Volume: 74, Issue:1

    Topics: Acquired Immunodeficiency Syndrome; Cell Division; Cell Line; Dexamethasone; Gene Expression Regulat

1989
Investigation of HTLV-3 serology in a renal transplant population.
    Transplantation, 1987, Volume: 43, Issue:2

    Topics: Antibodies, Viral; Azathioprine; Blood Transfusion; Cyclosporins; Histocompatibility Testing; HIV; H

1987